2 results
Approved WMOCompleted
To assess indacaterol (300 and 600 ug once daily via SDDPI) superiority in patients with COPD as compared to placebo with respect to 24 h post dose (through) FEV1 after 12 weeks of treatment.
Approved WMOCompleted
The main objective of the current proof-of-concept study is to explore the feasibility, acceptance and potential (clinical) added value of Sense-IT in a sample of psychiatric patients with ASD/ID/BPD and their psychiatric nurses.